Options for the treatment of type 2 diabetes mellitus (T2DM) and obesity have recently been
expanded by the results of several large clinical trials with incretin-based peptide therapies …

Introduction In this phase 4, multicentre, prospective, non-interventional PIONEER REAL
Netherlands study, we assessed clinical outcomes associated with once-daily oral …

Aims Real‐world data are required to support glucagon‐like peptide‐1 receptor agonist use
in type 2 diabetes (T2D). SURE France assessed once‐weekly semaglutide in adults with …

The prevalence of obesity in the United States and across the world continues to climb,
imparting increased risk of chronic disease. This impact is doubly felt in nephrology because …

Background We aimed to increase pharmacists' and regulatory agencies' awareness of
emerging issues regarding current practices of semaglutide use in the community that has …

Aims Individuals with lipodystrophies typically suffer from metabolic disease linked to
adipose tissue dysfunction including lipoatrophic diabetes. In the most severe forms of …

Purpose The present study aimed to systematically collect and synthesize available cost-
effectiveness studies of semaglutide in patients with obesity or overweight in comparison …

Objectives In recent years, new hypoglycaemic drugs that affect the incretin system have
become increasingly popular in the treatment of type 2 diabetes mellitus (T2DM): glucagon …

Heart failure (HF) stands as a formidable challenge in global healthcare casting a long
shadow over both morbidity and mortality. A significant interplay between HF and type 2 …

Prevalence of heart failure with preserved ejection fraction (HFpEF) is increasing, while
treatment options are inadequate. Hypertension and obesity-related metabolic dysfunctions …